Rituximab (RITUXAN, Genentech, Inc.), a monoclonal antibody, has been approved in combination with chemotherapy for pediatric patients 6-18 months with previously untreated, advanced staged, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), and Burkitt-like lymphoma (BLL).
The Lymphoma Research Foundation (LRF) encourages patients, survivors, and their care partners to take information and questions back to their individual health care providers as a way of creating a dialogue and partnership about their lymphoma and treatment.
For more than 23 years, Marla Briskman faced her lymphoma—enduring five relapses and six different treatments. What gave her hope? Incredible treatment advancements and the support of family, friends, and her husband and care partner, Rickey.
A lymphoma diagnosis not only affects the patient, but their care partners too. LRF Scientific Advisory Board member, Thomas M. Habermann, MD shares some helpful strategies on how to help cope with some of the pressures of being a care partner.
Undeterred by barriers and challenges associated with lymphoma and the
medical field, Dr. Sonali Smith’s work in the clinic and research realms, and
natural-born leadership puts her at the forefront of advancing cures for this
disease.